Table 4.
Variablesb | Multivariable-adjustedc | Multivariable-adjustedd | ||
---|---|---|---|---|
Odds ratios (95% CI) | p value | Odds ratios (95% CI) | p value | |
Estimated glomerular filtration rate (17.4 ml/min/1.73 m2) | 0.52 (0.38–0.70) | <0.001 | 0.55 (0.40–0.76) | <0.001 |
Log (24-hour urine albumin, 0.53 g/24 hours) | 1.44 (1.14–1.82) | 0.002 | 1.36 (1.05–1.77) | 0.02 |
Cystatin C (0.66 mg/L) | 1.67 (1.32–2.13) | <0.001 | 1.68 (1.29–2.18) | <0.001 |
Calcium (0.52 mg/dL) | 0.70 (0.55–0.89) | 0.003 | 0.72 (0.56–0.92) | 0.01 |
Phosphate (0.68 mg/dL) | 1.71 (1.34–2.19) | <0.001 | 1.55 (1.21–2.00) | <0.001 |
Log(fibroblast growth factor-23, 0.82 RU/mL) | 1.66 (1.30–2.11) | <0.001 | 1.66 (1.28–2.15) | <0.001 |
Log(total parathyroid hormone, 0.67 pg/mL) | 1.30 (1.02–1.65) | 0.03 | 1.24 (0.97–1.60) | 0.09 |
Alkaline phosphatase (31.2 U/L) | 1.04 (0.82–1.31) | 0.77 | 1.03 (0.80–1.33) | 0.81 |
Hemoglobin A1c (1.37%) | 1.39 (1.13–1.71) | 0.002 | 1.11 (0.85–1.44) | 0.44 |
Log (HOMA-insulin resistance, 0.62) | 1.32 (1.06–1.66) | 0.02 | 1.09 (0.84–1.40) | 0.53 |
Uric acid (1.84 mg/dL) | 0.96 (0.76–1.23) | 0.77 | 0.91 (0.70–1.17) | 0.44 |
Homocysteine (4.93 μmol/L) | 1.20 (0.95–1.52) | 0.12 | 1.08 (0.84–1.39) | 0.55 |
Fibrinogen (1.10 mg/dL) | 1.04 (0.83–1.32) | 0.72 | 1.01 (0.79–1.28) | 0.95 |
Log (high sensitive C-reactive protein, 0.80 mg/L) | 0.89 (0.70–1.13) | 0.35 | 1.00 (0.78–1.28) | 0.99 |
Log (interleukin-6, 0.57 pg/mL) | 0.91 (0.71–1.16) | 0.44 | 0.93 (0.72–1.21) | 0.60 |
Log (tumor necrosis factor-α, 0.52 mg/dL) | 1.36 (1.08–1.72) | 0.008 | 1.44 (1.12–1.86) | 0.004 |
Coronary artery calcification progression was defined as an annual increase of ≥100 Agatston units from the baseline to follow-up visit.
One standard deviation increase.
Adjusted for age, sex, race/ethnicity, clinical site, and baseline CAC score.
Adjusted for age, sex, race/ethnicity, clinical site, baseline CAC score, total cholesterol, HDL cholesterol, systolic BP, use of antihypertensive medications, diabetes, current smoking, history of CVD, use of statin medications, and physical activity.